Clinical Trial: Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07712029) titled 'Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive' on July 12.

Brief Summary: This phase II trial evaluates the combination of Becotatug Vedotin (MRG003), an EGFR-targeting ADC, and Pucotenlimab (HX008), a PD-1 inhibitor, in patients with high EGFR expressing advanced refractory solid tumors. The study is designed to assess clinical efficacy and safety, building on a strong synergistic rationale and promising early-phase data.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Advanced Refractory Solid Tumors EGFR Gene Overexpression

Intervention: DRUG: B...